|Mr. Dror Ben-Asher||Co-Founder, Chairman & CEO||448.42k||N/A||1966|
|Mr. Micha Ben-Chorin||Chief Financial Officer||339.01k||N/A||1969|
|Mr. Gilead Raday||Chief Operating Officer||361.68k||N/A||1975|
|Mr. Adi Frish||Chief Corp. & Bus. Devel. Officer||338.12k||N/A||1970|
|Mr. Guy Goldberg||Chief Bus. Officer||338.13k||N/A||1976|
|Dr. June S. Almenoff||Chief Scientific Officer||N/A||N/A||1957|
|Mr. Ben Martie||VP, Legal Affairs||N/A||N/A||N/A|
|Ms. Shani Maurice||VP of Bus. Devel. & Communications||N/A||N/A||N/A|
|Ms. Valerie Graceffa||VP of Sales||N/A||N/A||N/A|
|Mr. Rob Jackson||Sr. VP of Sales & Marketing||N/A||N/A||N/A|
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, with a planned Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), a SK2 selective inhibitor targeting various indications with a Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and in Phase 2 studies for irritable bowel syndrome with diarrhea; RHB-107, a Phase 2-stage serine protease inhibitor for cancer and inflammatory gastrointestinal diseases, and is also being evaluated for COVID-19; and RHB-106, an encapsulated bowel preparation. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.
RedHill Biopharma Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.